Coronary interventions

Coronary sinus narrowing for the treatment of refractory angina: a multicentre prospective open-label clinical study (the REDUCER-I study)

EuroIntervention 2021;17:561-568. DOI: 10.4244/EIJ-D-20-00873

Stefan Verheye
Stefan Verheye1, MD, PhD; Pierfrancesco Agostoni1, MD; Francesco Giannini2, MD; Jonathan M. Hill3, MD; Christoph Jensen4, MD; Steven Lindsay5, MD; Pieter R. Stella6, MD; Simon Redwood7, MD; Shmuel Banai8, MD; Maayan Konigstein8, MD
1. Cardiovascular Center, ZNA Middelheim Hospital, Lindendreef Antwerp, Belgium; 2. GVM Care & Research, Maria Cecilia Hospital, Cotignola, Italy; 3. King’s College Hospital, London, United Kingdom; 4. Elisabeth Hospital Essen, Essen, Germany; 5. Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom; 6. UMC Utrecht, Utrecht, the Netherlands; 7. St Thomas’ Hospital Cardiothoracic Centre, London, United Kingdom; 8. Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Background: The REDUCER-I study is a prospective (with a retrospective component), open-label, multi-centre, international, post-market study, which collects long-term data of patients with refractory angina treated with the Reducer. Here we present the overall clinical outcomes of the first 228 patients enrolled.

Aims: The aim of this study is to examine the safety and efficacy of the coronary sinus (CS) Reducer in improving angina severity and quality of life in patients suffering from angina pectoris, refractory to medical and interventional therapies.

Methods: REDUCER-I is a multicentre, non-randomised observational study. Enrolled patients had refractory angina pectoris Canadian Cardiovascular Society (CCS) class II-IV and were treated with Reducer implantation.

Results: In the first 228 patients (81% male, 68.3±9.6 years), the procedural success rate was 99%, with only one adjudicated possible procedural or device-related MACE. Mean CCS class decreased from 2.8±0.6 at baseline, to 1.8±0.7 at two years. Improvement in ≥1 CCS class was observed in 82%, and in ≥2 CCS classes in 31% of patients at two years. At baseline, 70% of the cohort were reported to be in CCS class III-IV; this portion was reduced to 15% at follow-up. Additional measured parameters of functional class and quality of life were also improved.

Conclusions: Interim results from the ongoing REDUCER-I study confirm the high safety profile of this therapy in patients suffering from refractory angina. The results also demonstrate sustained improvement in angina severity and in quality of life up to two years.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

clinical researchinnovationstable angina
Coronary interventionsStable CADOther coronary interventions
Read next article
Prognostic impact and clinical outcomes of coronary flow reserve and hyperaemic microvascular resistance

Latest news